



Stereodefined dinucleoside (3',5')-propionamidophosphonates and β -cyanoethylphosphonates and their incorporation into modified oligonucleotides

Lucyna A. Wozniak^{a,*}, Małgorzata Bukowiecka-Matusiak^{a,b},
Izabela Burzynska-Pedziwiatr^a, Wojciech J. Stec^{b,†}

^a Medical University of Lodz, Department of Structural Biology, Żeligowskiego 7/9, 90-752 Lodz, Poland

^b Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Lodz, Poland

ARTICLE INFO

Article history:

Received 11 September 2008

Revised 28 January 2009

Accepted 30 January 2009

Available online 5 February 2009

ABSTRACT

Base-catalyzed stereospecific anti-Markovnikov addition of dinucleoside (3',5')-*H*-phosphonates to the activated alkenes acrylamide and acrylonitrile resulting in the synthesis of P-chiral diastereomerically pure dinucleoside (3',5')-alkylphosphonates is reported.

© 2009 Published by Elsevier Ltd.

Chimeric oligonucleotides containing diastereomerically pure P-chiral nonionic methylphosphonate function(s) are convenient tools in molecular and structural biology to study the consequences of sequence-specific inhibition of gene expression, including potential therapeutic (antisense or antigene strategies) applications^{1,2} or the mechanisms of the action of ribozymes.^{3,4} Significant attention to their P-stereocontrolled synthesis, and particularly, in their stereodependent activity toward complementary DNA and RNA strands has been manifested since the late eighties.^{2,5} Recently, new data on the advantages of diverse functionalized alkylphosphonate modifications, preserving the colligate properties of methylphosphonates, that is, nuclease resistance and increasing cellular uptake, and comprising alkyl ligands accessible for further chemical modifications, have been disclosed.^{6,7} Herein, we report a new approach to the stereocontrolled synthesis of dinucleoside (3',5')- β -propionamidophosphonates (**2**) and β -cyanoethylphosphonates (**3**) of predetermined sense of P-chirality, their incorporation into model oligonucleotides, and the influence of such modification on their binding properties.

We assumed that Michael-type reaction of dinucleoside (3',5')-*H*-phosphonates (**1**) with acrylamide or acrylonitrile would provide compounds **2** or **3**, respectively. As chiral precursors of the β -propionamidophosphonates **2**⁸ and β -cyanoethylphosphonates **3**,⁹ we used diastereomerically pure dinucleoside (3',5')-*H*-phosphonates (**1**), as originally described by Seela et al.^{10,11} The starting dithymidyl (3',5')-*H*-phosphonates (**1**) were prepared using standard methods¹² and separated into pure diastereomers of **1** [B = Thy, ³¹P NMR (200 MHz, CDCl₃) 8.9 ppm (FAST-*R*_p) and

7.48 ppm (SLOW-*S*_p), *J*_{PH} = 717 Hz, FAB MS [M+1] = 981.2 (979.2 calcd)].

Before the dinucleoside *H*-phosphonates **1** were used as substrates (Scheme 1), the reaction conditions were studied applying model diethyl *H*-phosphonate (**5**) in reactions with (i) acrylamide and (ii) acrylonitrile (Scheme 2).

The addition of secondary phosphine oxides to the activated alkenes (Michael-type addition) is a synthetically important and widely documented reaction in the literature.¹³ In general, strong base activation is required, even for simple organophosphorous compounds, but the effectiveness of the addition process depends strongly on the structure of the alkene and the nature of the substituents at the phosphorous center. The reactivity of the corresponding *H*-phosphinates and *H*-phosphonates is much lower than that of the corresponding phosphinites, and the relatively harsh reaction conditions have limited the application of this reaction for the synthesis of substituted phosphonates.¹⁴ For the purpose of our studies, we had to elaborate the conditions under which modification of the internucleotide *H*-phosphonate bond in **1** would occur without modifying the reactive groups of the nucleosides.


As indicated in Table 1, in our studies we examined strong organic nonnucleophilic bases (DBU, p*K*_a = 24.32 in MeCN) and superbases (P₁-*t*Bu and P₂-Et),¹⁵ KOH (under solid phase conditions), and radical conditions (entry 2) for additions of diethyl *H*-phosphonate **5** to (i) acrylamide, resulting in the formation of (EtO)₂P(O)CH₂CH₂C(O)NH₂ (**6**) (Table 1). In all cases, only products of anti-Markovnikov addition were observed.⁶

Among the reactions specified in Table 1, only the conditions for entries 5–7 were chosen for further elaboration for reaction of acrylamide with dinucleoside (3',5')-*H*-phosphonates (**1**, B = Thy, Thy^{Bz}, Cyt^{Bz}).


* Corresponding author. Tel./fax: +48 426393121.

E-mail address: lucyna.wozniak@umed.lodz.pl (L.A. Wozniak).

† Tel.: +48 426803220; fax: +48 426819744.



Scheme 1.



Scheme 2.

Table 1

Addition of diethyl phosphite (5) to acrylamide (route i)

Entry	Catalyst ^a	Conditions	Yield (%)
1	DBU (10 equiv)	50 °C, 4 h	78
2	AIBN	80 °C, 2 h	—
3	$P_1\text{-tBu}$ (5 mol %)	50 °C, 1 h	51
4	$P_1\text{-tBu}$ (10 mol %)	50 °C, 1 h	47
5	$P_1\text{-tBu}$ (20 mol %)	50 °C, 1 h	80
6	$P_2\text{-Et}$ (10 mol %)	50 °C, 1 h	85
7	DBU (10 equiv)	50 °C, 1 h	46
8	$P_1\text{-tBu}$ (1 equiv)	50 °C, 1 h	18

^a All reactions were run in MeCN, except for entry 2 which was run in toluene.

Attempts to apply the same reaction conditions for addition to the C=C bond in acrylonitrile (route ii) failed, and even for diethyl *H*-phosphonate (5) the yields were less than satisfactory. However, in this case, activation with KOH was found to be efficient. To simplify the purification procedure and quenching of a strong base after reaction, we used supported KOH/Al₂O₃. This catalyst was loaded onto a small column, and the solution of both reactants in MeCN was passed through the column. Under two-phase conditions, the reactions were complete within a few minutes at room temperature with yields of products exceeding 90% and exclusive formation of (EtO)₂P(O)CH₂CH₂CN (7).¹⁶ In contrast, under the same conditions, no product was obtained in the reactions with acrylamide (route i).


Preliminary results have confirmed that the activation of dinucleotides **1** required specifically adjusted reaction conditions because there was no straightforward translation of the conditions from the model studies. The most satisfactory yield for the addition of **1** ($B^1 = B^2 = \text{Thy}$) to acrylamide was obtained when phosphazene ($P_1\text{-tBu}$, $pK_a = 26.9$ in MeCN)¹² was used as the catalyst at 50 °C for 15 min in THF as the solvent, leading to the expected dithymidyl (3',5')-propionamidophosphonate **2** in good yield (Scheme 3).

Neither extension of the reaction time nor further elevation of the temperature led to an increase in the yield of the expected products; the process of addition of the *H*-phosphonate to the

C=C bond of acrylamide was accompanied with a base modification.¹⁷ In this case (**1**, $B^1 = B^2 = \text{Thy}$), the MS analysis revealed a single modification of base ($B^1 = \text{Thy}$), identified (after separation by silica gel column chromatography) as 5'-*O*-DMT 3'-*N*-propionamido-thymidyl (5',3')-thymidine propionamidophosphonate (**2**) (MS FAB: 943.7 for **2** and 998.4 for the base substituted product, respectively). The use of diastereomerically pure **1** confirmed the stereospecific (retention of configuration at the P-atom) path of the addition. Starting from $R_P\text{-1}$ (³¹P NMR 7.62 ppm), only $R_P\text{-2}$ (³¹P NMR 27.4 ppm)¹⁸ was obtained, and from $S_P\text{-1}$ (³¹P NMR 8.75 ppm) diastereomerically pure $S_P\text{-2}$ (³¹P NMR 28.5 ppm) was synthesized (Scheme 3, Table 2).

To avoid the process of base modification, *N*³ base protection of the thymidine in **1** was used. The addition of diastereomerically pure **1** ($B^1 = \text{Thy}^{Bz}$, $B^2 = \text{Thy}$) to acrylamide was performed in THF in the presence of $P_1\text{-tBu}$ phosphazene (20 mol %) at 50 °C for 1 min. After cooling the reaction mixture (ice bath) and washing with 0.1 M citric acid, product **2** ($B^1 = \text{Thy}^{Bz}$, $B^2 = \text{Thy}$) was purified by silica gel column chromatography (³¹P NMR 35.2 ppm- SLOW-*S_P*, and 35.1 ppm- FAST-*R_P*, FAB $[M+H]^+ = 1008$ (calcd; m/z 1007) and $[M+H]^+ = 904$ (calcd; m/z 903; analysis after desilylation).¹⁹

Alternatively, 'solid phase' KOH/Al₂O₃ was used for the addition of dinucleotides **1** to acrylonitrile, and the corresponding dinucleoside (3',5')-β-cyanoethyl phosphonates **3** ($B = \text{Thy}$, ³¹P NMR 27.4 ppm-FAST, and 28.5 ppm-SLOW)²⁰ and **3** ($B^1 = B^2 = \text{Cyt}^{Bz}$, ³¹P NMR 27.54 ppm-FAST, 28.81 ppm-SLOW)²⁰ were obtained in good yields in a stereoretentive manner.¹⁹ The phosphorylation of $R_P\text{-2}$ with CIP(OCH₂CH₂CN)(iPr₂N) and DIPEA, as reported previously,²¹ resulted in 3'-*O* activated dinucleotide 3'-*O*-(*N*-diisopropyl β-cyanoethyl-phosphoramidate) **8** ($B = \text{Thy}^{Bz}$, ³¹P NMR 149.2, 149.1 ppm, and 33.46–32.29 ppm; $B = \text{Cyt}^{Bz}$, ³¹P NMR 149.62, 149.23 ppm, and 28.18, 27.54 ppm), whereas the phosphorylation of **3** yielded the corresponding dinucleotide 3'-*O*-(*N*-diisopropyl β-cyanoethyl-phosphoramidate) $R_P\text{-9}$ ($B = \text{Thy}^{Bz}$, ³¹P NMR 149.2, 149.0 ppm, and 33.47, 32.24 ppm). The 'manual' incorporation of the dimeric building blocks $R_P\text{-8}$ and $R_P\text{-9}$, or $S_P\text{-8}$ and $S_P\text{-9}$ into the oligomer connected to the solid support, followed by further



Scheme 3.

Table 2

Addition of dithymidyl (3',5')-*H*-phosphonate **1** ($B^1 = B^2 = \text{Thy}$) to acrylamide (route ii)

Entry	Substrate	Catalyst ^a	Conditions	Yield (%)
1	1 FAST	DBU (10 equiv)	50 °C, 3 h	—
2	1 FAST	P ₂ -Et (10 mol %)	20 °C, 2 h	—
3	1 FAST	P ₁ -tBu (10 mol %)	50 °C, 1 h	40
4	1 FAST	P ₁ -tBu (20 mol %)	50 °C, 1 h	70
5	1 FAST	P ₂ -Et (10 mol %)	50 °C, 1 h	14
6	1 FAST	P ₂ -Et (10% mol)	50 °C, 0.5 h	5

^a All reactions were run in MeCN, except for entry 5 which was run in THF.

Table 3

Thermodynamic data of hybrid duplexes formed with complementary DNA and RNA^a

Oligonucleotide	Thermodynamic data					
	DNA d(A) ₁₂			RNA r(A) ₁₂		
	<i>T</i> _m ^b (°C)	Δ <i>H</i> ^o (kcal/mol)	Δ <i>S</i> ^o (eu)	<i>T</i> _m ^b (°C)	Δ <i>H</i> ^o (kcal/mol)	Δ <i>S</i> ^o (eu)
12 d(T) ₁₂	37.0	79.6	228.7	27.8	64.1	184.4
Rp-10 d(TTT C ₃ H ₄ C(O)NH ₂ TT ₈)	37.2	59.6	166.8	24.5	64.0	186.5
Sp-10 d(TTT C ₃ H ₄ C(O)NH ₂ TT ₈)	31.0	69.6	203.7	—	—	—
Rp-11 d(TTT C ₂ H ₄ CN TT ₈)	34.3	84.8	246.6	27.9	75.3	222.8
Sp-11 d(TTT C ₂ H ₄ CN TT ₈)	28.0	67.9	196.6	—	—	—

^a d(A)₁₂ and r(A)₁₂ were used as the complementary templates, respectively.

^b T_m calculated from the first derivative,²³ with the error of temp not exceeding 0.3 °C.

chain elongation on synthesizer, yielded two chimeric oligonucleotides, d(TTTxTT₈) where $x = \text{CH}_2\text{CH}_2\text{C}(\text{O})\text{NH}_2$ for R_p-**10** and S_p-**10**, and $x = \text{P}(\text{O})\text{CH}_2\text{CH}_2\text{CN}$ for R_p-**11** and S_p-**11**, respectively.²²

From the preliminary data given in Table 3, the relationship between the absolute configuration at the phosphorus atom of the internucleotide alkylphosphonate linkage and the stability of the hybrid duplexes with complementary DNA and RNA templates is

apparent.²⁴ For the analyzed sequences, the chimeric oligonucleotides with *R*_P-phosphonates (**10a** and **11a**) elicit stronger affinity toward complementary DNA than those with the *S*_P-modifications, and are comparable to nonmodified d(T)₁₂-**12**. Analogous dependence was observed earlier for methylphosphonate and methylphosphonothioate analogs of 2'-OMe-RNA.^{5a,21} Incorporation of nonpolar phosphonate modification in oligonucleotides **10** and **11** is connected with noteworthy changes of entropy values, suggesting a considerable change of solvation pattern.

Further studies on the synthesis and incorporation of dimeric building blocks **8** and **9** via phosphoramidite solid phase synthesis into different sequence-specific oligonucleotides, evaluation of the properties of these chimeric oligonucleotides, and further functionalization of P-pendant groups are in progress.

Acknowledgments

This project was supported by the Polish Academy of Sciences and the Medical University of Lodz (50217961 for LW).

Supplementary data

Supplementary data (^1H and ^{31}P NMR and MALDI TOF spectra of compounds) associated with this article can be found, in the online version, at [doi:10.1016/j.tetlet.2009.01.153](https://doi.org/10.1016/j.tetlet.2009.01.153).

References and notes

1. Crooke, S. T. *Annu. Rev. Med.* **2004**, 55, 61.
2. Reynolds, M. A.; Hogrefe, R. I.; Jaeger, J. A.; Schwartz, D. A.; Riley, T. A.; Marvin, W. B.; Daily, J.; Vaghefi, M. M.; Beck, T. A.; Knowles, S. A.; Klem, R. E.; Arnold, L. J., Jr. *Nucleic Acids Res.* **1996**, 24, 4584.
3. Warashina, M.; Nawrot, B.; Obika, S.; Wozniak, L. A.; Kuwabara, T.; Imanishi, T.; Stec, W. J.; Taira, K. In *Synthetic Nucleic Acids as Inhibitors of Gene Expression: Mechanisms*; Khachigian, L. M., Ed.; Applications and Therapeutic Implications; CRC Press: Boca Raton, FL, 2005; pp 95–113.
4. (a) Okonogi, T. M.; Alley, S. C.; Harwood, E. A.; Hopkins, P. B.; Robinson, B. H. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, 99, 4156; (b) Hardwidge, P. R.; Zimmerman, J.

- M.; Maher, L. J. *Nucleic Acids Res.* **2002**, *30*, 1879; (c) Gao, R.; Claeboe, Ch. D.; Eisenhauer, B. M.; Hecht, S. M. *Biochemistry* **2004**, *43*, 6167; (d) Tian, L.; Claeboe, Ch. D.; Hecht, S. M.; Shuman, S. *Structure* **2004**, *12*, 31; (e) Kurpiewski, M. R.; Engler, L. E.; Wozniak, L. A.; Kobylanska, A.; Koziolkiewicz, M.; Stec, W. J.; Jen-Jacobson, L. *Structure* **2004**, *12*, 1775; (f) Liu, J.; Déclais, A.-C.; McKinney, A. S.; Ha, T.; Norman, D. G.; Lilley, D. M. J. *Chem. Biol.* **2005**, *12*, 217.
5. (a) Leśnikowski, Z. J.; Jaworska-Maślanka, M.; Stec, W. J. *Nucleosides Nucleotides* **1991**, *10*, 733; (b) Leśnikowski, Z. J.; Jaworska, M.; Stec, W. J. *Nucleic Acids Res.* **1988**, *16*, 11675.
 6. Sheehan, D.; Lunstad, B.; Yamada, Ch. M.; Stell, B. G.; Caruthers, M. H.; Dellinger, D. J. *Nucleic Acids Res.* **2003**, *31*, 4109.
 7. Yamada, Ch. M.; Dellinger, D. J.; Caruthers J. *Am. Chem. Soc.* **2006**, *128*, 5251.
 8. Fathi, R.; Huang, Q.; Coppola, G.; Delaney, W.; Teasdale, R.; Krieg, A. M.; Cook, A. F. *Nucleic Acids Res.* **1994**, *22*, 5416.
 9. Fathi, R.; Delaney, W.; Huang, Q.; Cook, A. F. *Nucleosides Nucleotides* **1995**, *14*, 1725.
 10. The yields of the condensation between 5'-O-DMT-nucleoside 3'-O-H-phosphonates and 3'-O-protected nucleosides, activated by adamantoyl chloride were very high (90% to quantitative, as estimated from ^{31}P NMR), however, separation of the diastereomers caused a significant decrease of the final yields. Isomers SLOW were usually obtained in low yields (10–15%) only, depending on the sequence and scale of purification. Compound **1** (B = Thy) (FAST): ^1H NMR (500 MHz, CDCl_3): 6.4 (H1'), 6.0 (H1'), 5.2 (3H'), 4.5 (H3'), 4.3 (H5'), 4.2 (4'H, 5''H), 4.0 (4'H), 3.5 (5'H), 3.3 (5''H), 2.6 (2'H), 2.4 (2''H), 2.3 (2'H, 2''H), 6.89 (P-H, $J_{\text{P-H}} = 717$ Hz) Compound **1** (SLOW) ^1H NMR: 6.4 (1H'), 6.2 (1H'), 5.3 (3H'), 4.4 (3H'), 4.3 (H 4'), 4.2 (H 5'), 4.1 (H 5'), 3.9 (H 4'), 3.5 (H 5'), 3.4 (H5''), 2.7 (H 2'), 2.6 (H2''), 2.2 (H 2'), 2.1 (H2''), 6.9 (P-H, $J_{\text{P-H}} = 717$ Hz), MS FAB $[M+1] = 927.1$ Compound **1** (B = Cyt^{Bz}): ^{31}P NMR (81.03 MHz CDCl_3): 7.64 ppm (FAST), 8.36 ppm (SLOW), $J_{\text{P-H}} = 720$ Hz, MS FAB $[M+1] = 1125.3$ 9 (calcd; 1124.23)
 11. Seela, F.; Kretschmer, U. J. *Org. Chem* **1991**, *12*, 3861.
 12. Stawiński, J.; Strömberg, R. In *Current Protocols in Nucleic Acid Chemistry*; Beaucage, S. L., Bergstrom, D. E., Herdewijn, P., Matsuda, A., Eds.; John Wiley and Sons, 2005.
 13. (a) Enders, D.; Saint-Dizier, A.; Lannou, M. I.; Lenzen, A. *Eur. J. Org. Chem.* **2006**, *29*; (b) Liu, X.; Hu, X. E.; Tian, X.; Mazur, A.; Ebetino, F. H. J. *Organomet. Chem.* **2002**, *646*, 212; (c) Bochwic, B.; Michalski, J. *Nature* **1951**, *167*, 1035.
 14. (a) Simoni, D.; Invidiata, F. P.; Manfredini, M.; Lampronti, I.; Rondanin, R.; Roberti, P.; Pollini, M. G. *Tetrahedron Lett.* **1998**, *39*, 7615; (b) Haynes, R. K. *Tetrahedron Lett.* **1996**, *37*, 4729; (c) Yamashita, M.; Tamada, Y.; Iida, A.; Oshikawa, T. *Synthesis* **1990**, 420.
 15. Verkade, J. G. *Top. Curr. Chem.* **2003**, *223*, 3.
 16. Al_2O_3 (5 g) was added to 1 M KOH (3 g KOH in 50 mL H_2O), concentrated under vacuum, washed with dry EtOH (4 times), concentrated, and dried under high vacuum at room temperature: Semenzin, D.; Moghadam, G. M.; Albouy, D.; Diallo, O.; Koenig, M. J. *Org. Chem.* **1997**, *62*, 2414.
 17. The ^1H NMR analysis revealed that a single base modification occurred selectively on the 5'-thymidine to the modified internucleotide bond.
 18. The absolute configurations at phosphorus were assigned based on ^{31}P and ^1H NMR (COSY) analysis.
 19. FAST: ^1H NMR (500 MHz, CDCl_3) 6.4(H1'), 6.1 (H1'), 5.2 (H3'), 4.4 (H3'), 4.3 (H4'), 4.2 (H5'/5''), 4.0 (H4'), 3.6 (H5'), 3.4 (H5''), 2.4 (H2'), 2.3 (H2'), 2.3 (H2''), 6.8 (P- $\text{CH}_2\text{CH}_2\text{CN}$), 1.4 (P- $\text{CH}_2\text{CH}_2\text{CN}$).
 20. Compounds **3** (B = Cyt^{Bz}) were prepared from a R_p , S_p mixture of **1** (diastereomeric ratio 2:1), and separated into diastereomers after addition and 3'-O-deprotection.
 21. Wozniak, L. A.; Bukowiecka-Matusiak, M.; Janicka, M. *Eur. J. Org. Chem.* **2005**, 5189.
 22. MALDI TOF spectra confirmed the constitution of both oligonucleotides: R_p -**10** (found 3941.1, calcd; m/z 3943.2) and R_p -**11** (found 3925.8, calcd; m/z 3924.2)
 23. Evertsz, E. M.; Karsten, R.; Jovin, T. M. *Nucleic Acids Res.* **1994**, *22*, 3293.
 24. Oligonucleotides **10** or **11** and the corresponding templates were mixed together in 10 mM Tris buffer, 10 mM MgCl_2 , and 100 mM NaCl (pH 7.4) at a total 4.1 M concentration of duplex, heated at 60 °C for 5 min, and kept overnight at 4 °C. Melting profiles were recorded in the range 3–90 °C, in both directions, with a temperature gradient of 0.3 °C/min.